Drugs / Autologous HuCD19 ( Anti-CD19)CAR T cells
Autologous HuCD19 ( Anti-CD19)CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06364423 | Sep 2024 → Jul 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoblastic lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous HuCD19 ( Anti-CD19)CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06364423 ↗ |
| Action | Deplete | “The collected T cells will be gene edited to make them attack cells with CD19.” NCT06364423 ↗ |
| Modality | Cell therapy | “Autologous T cells genetically modified to express CARs targeting the B-cell antigen CD19” NCT06364423 ↗ |